Drug Profile
MTI 101
Alternative Names: MTI-101Latest Information Update: 22 May 2022
Price :
$50
*
At a glance
- Originator Modulation Therapeutics
- Class Cyclic peptides; Peptidomimetics; Small molecules
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung cancer; Prostate cancer
- No development reported Multiple myeloma
Most Recent Events
- 22 May 2022 Preclinical trials in Lung cancer in USA (unspecified route) before May 2022 (Modulation Therapeutics pipeline, May 2022)
- 22 May 2022 Preclinical trials in Prostate cancer in USA (unspecified route) before May 2022 (Modulation Therapeutics pipeline, May 2022)
- 22 May 2022 Modulation Therapeutics plans to files an IND application in first quarter of 2021 (Modulation Therapeutics website, May 2022)